International Association for the Study of Lung Cancer World Conference

kalhh / Pixabay

A Combination of Benmelstobart, Anlotinib, and Chemotherapy Improves Survival Rates in SCLC, Study Suggests

Post author:Jessica Lynn
Post published:October 16, 2023
Post category:Small cell lung cancer

Advancing patient outcomes hinges on the development of targeted treatments, particularly in conditions with grim prognoses such as small cell lung cancer (SCLC), which typically has a life expectancy…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

A Combination of Benmelstobart, Anlotinib, and Chemotherapy Improves Survival Rates in SCLC, Study Suggests

Metastatic Breast Cancer: Navigating Grief

Rethinking What It Means to Live With Acromegaly

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

Let’s Work Together!

Keep Up to Date

Learn More